title: Evaluation of butyrate-induced production of a mannose-6-phosphorylated therapeutic enzyme using parallel bioreactors.
abstract: Bioreactor process changes can have a profound effect on the yield and quality of biotechnology products. Mannose-6-phosphate (M6P) glycan content and the enzymatic catalytic kinetic parameters are critical quality attributes (CQAs) of many therapeutic enzymes used to treat lysosomal storage diseases (LSDs). Here, we have evaluated the effect of adding butyrate to bioreactor production cultures of human recombinant β-glucuronidase produced from CHO-K1 cells, with an emphasis on CQAs. The β-glucuronidase produced in parallel bioreactors was quantified by capillary electrophoresis, the catalytic kinetic parameters were measured using steady-state analysis, and mannose-6-phosphorylation status was assessed using an M6P-specific single-chain antibody fragment. Using this approach, we found that butyrate treatment increased β-glucuronidase production up to approximately threefold without significantly affecting the catalytic properties of the enzyme. However, M6P content in β-glucuronidase was inversely correlated with the increased enzyme production induced by butyrate treatment. This assessment demonstrated that although butyrate dramatically increased β-glucuronidase production in bioreactors, it adversely impacted the mannose-6-phosphorylation of this LSD therapeutic enzyme. This strategy may have utility in evaluating manufacturing process changes to improve therapeutic enzyme yields and CQAs.
authors.affiliation: Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Chikkathur N
authors.initials: CN
authors.lastname: Madhavarao
authors.forename: Cyrus D
authors.initials: CD
authors.lastname: Agarabi
authors.forename: Lily
authors.initials: L
authors.lastname: Wong
authors.forename: Sven
authors.initials: S
authors.lastname: Müller-Loennies
authors.forename: Thomas
authors.initials: T
authors.lastname: Braulke
authors.forename: Mansoor
authors.initials: M
authors.lastname: Khan
authors.forename: Howard
authors.initials: H
authors.lastname: Anderson
authors.forename: Gibbes R
authors.initials: GR
authors.lastname: Johnson
mesh_terms: D000818:Animals; D019149:Bioreactors; D002087:Butyrates / Q000737:chemistry / Q000494:pharmacology*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005966:Glucuronidase / Q000096:biosynthesis* / Q000627:therapeutic use; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D008360:Mannosephosphates / Q000737:chemistry / Q000494:pharmacology; D010766:Phosphorylation; D011134:Polysaccharides / Q000737:chemistry
chemical_list: D002087:Butyrates; D008360:Mannosephosphates; D011134:Polysaccharides; C027693:mannose-6-phosphate; D005966:Glucuronidase
keywords: bioreactors; capillary electrophoresis; enzyme replacement therapies; enzymes; lysosomal storage diseases; mannose-6-phosphate
references.citation: Biotechnol Bioeng. 2008 May 1;100(1):189-94
references.pmid: 18023047
references.citation: J Biotechnol. 2004 Sep 9;112(3):323-35
references.pmid: 15313009
references.citation: Mol Biotechnol. 2000 Jul;15(3):249-57
references.pmid: 10986701
references.citation: Annu Rev Med. 2006;57:283-96
references.pmid: 16409150
references.citation: Biotechnol Bioeng. 2010 Apr 15;105(6):1048-57
references.pmid: 20039310
references.citation: Biotechnol Prog. 2008 Jul-Aug;24(4):898-906
references.pmid: 19194899
references.citation: Biotechnol Prog. 2005 Jan-Feb;21(1):22-30
references.pmid: 15903237
references.citation: Protein Expr Purif. 2001 Jun;22(1):75-81
references.pmid: 11388802
references.citation: Biotechnol Bioeng. 2008 Aug 15;100(6):1193-204
references.pmid: 18351681
references.citation: Am J Pathol. 2010 Jul;177(1):240-7
references.pmid: 20472886
references.citation: Adv Biochem Eng Biotechnol. 2006;101:119-64
references.pmid: 16989260
references.citation: Biochim Biophys Acta. 2009 Apr;1793(4):605-14
references.pmid: 19046998
references.citation: J Pediatr. 1975 Mar;86(3):388-94
references.pmid: 803560
references.citation: Eur J Pharm Biopharm. 2011 Jun;78(2):184-8
references.pmid: 21256214
references.citation: J Lab Clin Med. 1973 Dec;82(6):969-77
references.pmid: 4202279
references.citation: Anal Chem. 2011 Jul 1;83(13):5344-52
references.pmid: 21599028
references.citation: Biotechnol Adv. 2010 May-Jun;28(3):385-94
references.pmid: 20156545
references.citation: J Pediatr. 1973 Feb;82(2):249-57
references.pmid: 4265197
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2616-21
references.pmid: 18268347
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3083-8
references.pmid: 14976248
references.citation: Methods Mol Biol. 2005;308:107-21
references.pmid: 16082030
references.citation: Biochim Biophys Acta. 1995 Apr 24;1270(2-3):103-36
references.pmid: 7727535
references.citation: Cytotechnology. 2001 Jul;36(1-3):71-83
references.pmid: 19003317
references.citation: Biotechnol Bioeng. 2000-2001;71(3):184-93
references.pmid: 11291028
references.citation: J Biol Chem. 2010 Jul 2;285(27):20423-7
references.pmid: 20430897
references.citation: Pediatr Ann. 2009 Aug;38(8):448-55
references.pmid: 19725195
references.citation: J Biotechnol. 2006 Apr 20;122(4):463-72
references.pmid: 16253368
references.citation: Nat Rev Mol Cell Biol. 2003 Mar;4(3):202-12
references.pmid: 12612639
references.citation: Biotechnol Appl Biochem. 2005 Jun;41(Pt 3):265-72
references.pmid: 15504104
references.citation: Biotechnol Bioeng. 2001 Jan 5;72(1):55-61
references.pmid: 11084594